Gastrointestinal Hemorrhage

Edoxaban (Savaysa, Daiichi Sankyo) or vitamin K antagonist in patients with atrial fibrillation after transcatheter aortic valve replacement.

In the ENVISAGE-TAVI AF trial, edoxaban was noninferior to vitamin K antagonists for adverse clinical events and was associated with increased major bleeding in patients with AF who underwent transcatheter aortic valve replacement.

New endoscopic techniques and changes in the pharmacologic landscape prompted an update in guidelines for managing patients with nonvariceal upper GI bleeding.